Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lupus Arthritis, Systemic Lupus Erythematosus Clear all
Recruiting Phase 1 Interventional

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562
View directory record Official record
Conditions
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Interventions
AB-101, Rituximab, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 10, 2026, 4:07 AM EDT
Completed No phase listed Observational

Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases

NCT00069342
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Arthritis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 10, 2026, 4:07 AM EDT
Not listed Not applicable Interventional

Delivery of Enhance Fitness Trial

NCT05275348
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis, Fibromyalgia, Gout, Osteoarthritis, Lupus or SLE
Interventions
Tele-Enhance Fitness, In-person Enhance Fitness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 10, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
ABBV-519
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Anniston, Alabama • Tustin, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 4:07 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

NCT02418273
View directory record Official record
Conditions
Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis, Systemic Lupus Erythematosis, Vasculitis, Glucocorticoid-induced Osteoporosis
Interventions
denosumab
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 10, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262727
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 10, 2026, 4:07 AM EDT
Withdrawn No phase listed Observational

Clinical Performance of BioCLIA Ro60

NCT03204448
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome
Interventions
BioCLIA Ro60
Device
Lead sponsor
HOB Biotech Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 10, 2026, 4:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance

NCT01180361
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 10, 2026, 4:07 AM EDT
Completed No phase listed Observational

Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor

NCT02920346
View directory record Official record
Conditions
Sjogren's Syndrome, Neonatal Systemic Lupus Erythematosus, Fetal Heart Block Complete
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 10, 2026, 4:07 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Clinical Trial for CTD-ILD Treatment

NCT01424033
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Disease
Interventions
N-Acetylcysteine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 10, 2026, 4:07 AM EDT
Not listed Not applicable Interventional

Testing Pediatric Rheumatology Diagnostic Decision Support in Clinical Use

NCT03501667
View directory record Official record
Conditions
Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
Interventions
Use of decision support tool, Use of UpToDate
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
25 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 10, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

NCT00010335
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions
Stem Cell Transplantation, CD34 selection
Procedure · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 10, 2026, 4:07 AM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 10, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 10, 2026, 4:07 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 10, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

FolateScan in Autoimmune Disease

NCT00588393
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis, Multiple Sclerosis, Crohn's Disease, Systemic Lupus Erythematosus
Interventions
FolateScan (Technetium Tc 99mEC20)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 10, 2026, 4:07 AM EDT
Completed Not applicable Interventional

Prevention of Arthritis-Related Work Disability

NCT00000416
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
Interventions
Rehabilitation counseling
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 10, 2026, 4:07 AM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 10, 2026, 4:07 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

NCT02741362
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions
Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
Other
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 10, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724
View directory record Official record
Conditions
Dry Eye Syndrome, Systemic Lupus Erythematosus
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 10, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02780674
View directory record Official record
Conditions
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Interventions
MEDI7734, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 10, 2026, 4:07 AM EDT
Not yet recruiting Phase 1 Interventional

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

NCT07729995
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
Interventions
LMY-922
Biological
Lead sponsor
Luminary Therapeutics
Industry
Eligibility
16 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 10, 2026, 4:07 AM EDT
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 10, 2026, 4:07 AM EDT
Completed Not applicable Interventional Results available

Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology

NCT05116163
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Arthritis, Osteoarthritis
Interventions
Individuation Intervention plus implicit bias educational modules, Implicit bias educational modules
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 10, 2026, 4:07 AM EDT